Truist Securities Reiterates Buy on Tenet Healthcare, Maintains $92 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reiterated a Buy rating on Tenet Healthcare (NYSE:THC) and maintained a $92 price target for the company's stock.

November 20, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst David Macdonald reiterated a Buy rating on Tenet Healthcare with a maintained price target of $92.
The reiteration of a Buy rating and the maintenance of a $92 price target by a Truist Securities analyst could positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Tenet Healthcare. The confidence in the stock by a reputable analyst often acts as a bullish signal to the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100